Uncategorized Archives - Page 4 of 134

TuesdayJan 28, 2025 10:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

Proprietary R&D is led by a world-class team of medicinal chemists and industry veterans, ensuring innovative product development. A first-to-market product, unbuzzd addresses a fast-expanding consumer category, with 300% growth expected by 2030. Lucid-MS, a potential multi-billion-dollar asset, represents a significant breakthrough in the treatment of demyelinating diseases, supported by an expedited regulatory pathway. Strategic equity and royalty agreements with Celly Nutrition for consumer-focused alcohol misuse treatments provide an additional revenue stream. Quantum BioPharma is strategically positioned in two high-growth sectors: hangover remedies and MS therapeutics. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative…

ThursdayJan 23, 2025 10:45 am

Astiva Health Achieves 188% Membership Growth as It Strengthens Medicare Advantage Leadership

Astiva Health now serves more than 30,000 members, an increase that reflects the growing demand for the company’s unique, culturally aligned health care model. Astiva’s focus on multilingual support and tailored healthcare solutions are some of the key factors driving its success. The increase in membership comes as Astiva earned a prestigious 4-star CMS rating for 2025, placing it among the top-rated Medicare Advantage providers in California. The high CMS rating comes with up to $1,200 more per beneficiary annually compared to lower-rated plans. Astiva will use the increased funding to expand its offering with additional member benefits and to…

FridayJan 17, 2025 8:00 am

Adageis, Focused on Empowering Healthcare Providers in the Shift to Provider-Centric, Value-Based Care

Adageis focuses on empowering healthcare providers with tools and insights to excel in value-based care models, using a provider-centric approach. The company’s patented AI solutions enable providers to identify high-risk patients and address care gaps effectively. Its ProActive Care Platform integrates seamlessly with existing EHR systems to enhance patient outcomes and operational efficiency. A unique offering in the healthcare technology space, the platform offers flexible integration, proactive efficiency, and advanced predictive analysis capabilities. Adageis, a healthcare technology company, is taking a bold stance in reshaping the healthcare landscape by prioritizing providers in the transition to value-based care. Unlike traditional models…

TuesdayJan 14, 2025 10:00 am

Why the Need to Protect Healthcare Data Has Become More Imperative

Reliance on technology in the healthcare industry is growing day by day, a positive, as it has greatly increased efficiency. However, the increasing use of software has also made the industry a target for cyberattacks, which poses a huge threat to healthcare providers. For instance, clinics and hospitals may be forced to cancel appointments, postpone surgeries, and even send ambulances to other facilities to avoid putting patients at risk. In most cases, attackers encrypt information then threaten to release it if the ransom isn’t paid. An analyst of cyber security threats at Vercara, Richard Wallace, reveals that in the last…

WednesdayJan 08, 2025 8:45 am

Adageis, at the Forefront of AI-Driven Transformation in Healthcare

AI promises to revolutionize patient care by improving efficiency, reducing costs and enabling value-based care models. AI-driven risk engines enable providers to pinpoint high-risk patients and proactively address health issues. Combining advanced AI-driven analytics with flexible EHR integration through its ProActive Care Platform, Adageis helps providers meet revenue and care quality metrics in a value-driven healthcare landscape. The Adageis platform facilitates real-time patient oversight, improving outcomes beyond traditional visits. Artificial intelligence is rapidly reshaping healthcare by enabling precision medicine, predictive analytics and operational efficiency. As the industry transitions toward value-based care, AI plays a crucial role in meeting quality metrics,…

TuesdayJan 07, 2025 8:45 am

Adageis Is Already Positioned to Support Healthcare Shift to a Value-Based Care Model

Transition to a value-based care approach prioritizes quality outcomes over service volume, but calls for a dramatic overhaul of infrastructure, culture and operations. Shifting to value-based care means significant changes in mindset and practice among clinicians, while also disrupting traditional revenue models, creating initial financial risks. Leadership, data analytics, care coordination, and payer collaboration, are key to successful implementation. Adageis is structured to support providers during this transformation, with its unique offering of tools and solutions to simplify the necessary moves, including AI-driven analytics and patient-focused care solutions. The company’s platform is designed to help healthcare organizations optimize care delivery…

MondayDec 30, 2024 8:45 am

Adageis Embracing New Era for Value-Based Care Amid Healthcare System Transition from CMS-HCC V24 to V28

The Centers for Medicare and Medicaid Services’ switch from the Hierarchical Condition Categories model V24 to the modernized V28 brings about an updated disease classification structure that aligns with current healthcare standards. V28 enhances the accuracy of Medicare Advantage payments, impacting conditions like diabetes and dementia. Under the new model, HCC categories rise from 86 to 115, with updated inclusion and exclusion criteria. The transition aligns closely with Adageis’s mission of revolutionizing patient care through innovative value-based care solutions, positioning the company for growth. Adageis aims to improve healthcare delivery by helping providers streamline operations and focus on delivering quality…

ThursdayDec 26, 2024 10:15 am

Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application

The $10 million loan agreement, carrying a 12% interest rate and secured by all assets of Clene, was signed with three lenders affiliated with the company. The funds will be used to repay the remaining $7.9 million debt of an Avenue Capital Group loan, and will improve the company’s cash position, enabling it extra runway to generate additional data to support the new drug application of CNM-Au8 for ALS. The FDA earlier suggested that Clene leverage additional neurofilament light (“NfL”) data from the company’s three Expanded Access Protocols (compassionate use programs) and the HEALEY ALS Platform Trial to support earlier…

FridayDec 13, 2024 1:00 pm

Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company’s 2024 milestones and strategic initiatives for 2025. The full webcast is available here: https://youtu.be/NA3kCUZZIpI. During the webcast, Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, detailed significant progress in the company’s pivotal Phase 3 studies for Buntanetap, its lead drug candidate targeting neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. These studies aim to demonstrate both symptomatic relief and disease-modifying effects, aligning with Annovis Bio’s mission to address the…

FridayDec 13, 2024 12:15 pm

Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS

The FDA asked for additional Neurofilament Light (“NfL”) data from the company’s three Expanded Access Protocols to support earlier clinical trial findings. The company has already begun collecting and analyzing this data, with plans to complete the process in Q2 2025 and then submit a New Drug Application (“NDA”) for CNM-Au8 by mid-2025. A follow-up meeting with the FDA will be held early next year to discuss and finalize the statistical analysis plan for the EAP NfL biomarker analyses. The company is meanwhile preparing a confirmatory Phase 3 trial (“RESTORE-ALS”) to evaluate the survival benefit of CNM-Au8 with initial participant…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

Astiva Health Achieves 188% Membership Growth as It Strengthens Medicare Advantage Leadership

Adageis, Focused on Empowering Healthcare Providers in the Shift to Provider-Centric, Value-Based Care

Why the Need to Protect Healthcare Data Has Become More Imperative

Adageis, at the Forefront of AI-Driven Transformation in Healthcare

Adageis Is Already Positioned to Support Healthcare Shift to a Value-Based Care Model

Adageis Embracing New Era for Value-Based Care Amid Healthcare System Transition from CMS-HCC V24 to V28

Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application

Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast

Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search